References
-
1.
Carter-Timofte ME, Jørgensen SE, Freytag MR, Thomsen MM, Brinck Andersen N, Al-Mousawi A, et al. Deciphering the Role of Host Genetics in Susceptibility to Severe COVID-19. Front Immunol. 2020;11. https://doi.org/10.3389/fimmu.2020.01606.
-
2.
Mahmud R, Rahman MM, Alam I, Ahmed KGU, Kabir A, Sayeed S, et al. Ivermectin in combination with doxycycline for treating COVID-19 symptoms: a randomized trial. J Int Med Res. 2021;49(5):3000605211013550. [PubMed ID: 33983065]. [PubMed Central ID: PMC8127799]. https://doi.org/10.1177/03000605211013550.
-
3.
Rahimi A, Samimagham HR, Azad MH, Hooshyar D, Arabi M, KazemiJahromi M. The efficacy of N-Acetylcysteine in severe COVID-19 patients: A structured summary of a study protocol for a randomised controlled trial. Trials. 2021;22(1):271. [PubMed ID: 33845881]. [PubMed Central ID: PMC8040363]. https://doi.org/10.1186/s13063-021-05242-4.
-
4.
Samimagham HR, Hassani Azad M, Haddad M, Arabi M, Hooshyar D, KazemiJahromi M. The Efficacy of Famotidine in improvement of outcomes in Hospitalized COVID-19 Patients: A structured summary of a study protocol for a randomised controlled trial. Trials. 2020;21(1):848. [PubMed ID: 33050945]. [PubMed Central ID: PMC7552598]. https://doi.org/10.1186/s13063-020-04773-6.
-
5.
Soleimanpour S, Yaghoubi A. COVID-19 vaccine: where are we now and where should we go? Expert Rev Vaccines. 2021;20(1):23-44. [PubMed ID: 33435774]. [PubMed Central ID: PMC7898300]. https://doi.org/10.1080/14760584.2021.1875824.
-
6.
Xia S, Zhang Y, Wang Y, Wang H, Yang Y, Gao GF, et al. Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBIBP-CorV: a randomised, double-blind, placebo-controlled, phase 1/2 trial. Lancet Infect Dis. 2021;21(1):39-51. [PubMed ID: 33069281]. [PubMed Central ID: PMC7561304]. https://doi.org/10.1016/S1473-3099(20)30831-8.
-
7.
Doroftei B, Ciobica A, Ilie OD, Maftei R, Ilea C. Mini-Review Discussing the Reliability and Efficiency of COVID-19 Vaccines. Diagnostics (Basel). 2021;11(4). [PubMed ID: 33804914]. [PubMed Central ID: PMC8063839]. https://doi.org/10.3390/diagnostics11040579.
-
8.
Zhu FC, Guan XH, Li YH, Huang JY, Jiang T, Hou LH, et al. Immunogenicity and safety of a recombinant adenovirus type-5-vectored COVID-19 vaccine in healthy adults aged 18 years or older: a randomised, double-blind, placebo-controlled, phase 2 trial. Lancet. 2020;396(10249):479-88. [PubMed ID: 32702299]. [PubMed Central ID: PMC7836858]. https://doi.org/10.1016/S0140-6736(20)31605-6.